On Invalid Date, Terns Pharmaceuticals (NASDAQ: TERN) reported Q3 2023 earnings per share (EPS) of -$0.42, up 4.55% year over year. Total Terns Pharmaceuticals earnings for the quarter were -$29.77 million. In the same quarter last year, Terns Pharmaceuticals's earnings per share (EPS) was -$0.44.
As of Q4 2023, Terns Pharmaceuticals's earnings has grown year over year. Terns Pharmaceuticals's earnings in the past year totalled -$85.01 million.
What was TERN's revenue last quarter?
On Invalid Date, Terns Pharmaceuticals (NASDAQ: TERN) reported Q3 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Terns Pharmaceuticals's revenue was $0.00.
What was TERN's revenue growth in the past year?
As of Q4 2023, Terns Pharmaceuticals's revenue has grown -100% year over year. This is 212.01 percentage points lower than the US Biotechnology industry revenue growth rate of 112.01%. Terns Pharmaceuticals's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.